What is the projected market valuation for the GERD and NERD Treatment Market in 2035?

The projected market valuation for the GERD and NERD Treatment Market in 2035 is 3437.92 USD Million. Read More

What was the overall market valuation for the GERD and NERD Treatment Market in 2024?

The overall market valuation for the GERD and NERD Treatment Market in 2024 was 2052.29 USD Million. Read More

What is the expected CAGR for the GERD and NERD Treatment Market from 2025 to 2035?

The expected CAGR for the GERD and NERD Treatment Market during the forecast period 2025 - 2035 is 4.76%. Read More

Which treatment type segment had the highest valuation in 2024?

In 2024, the Proton Pump Inhibitors segment had the highest valuation, ranging from 800.0 to 1300.0 USD Million. Read More

What are the projected valuations for the Oral route of administration by 2035?

The projected valuations for the Oral route of administration by 2035 are expected to range from 1700.0 to 1025.0 USD Million. Read More

How does the market for Pediatric patients compare to Geriatric patients in 2024?

In 2024, the market for Pediatric patients was valued between 300.0 and 500.0 USD Million, whereas the Geriatric segment was valued between 400.0 and 700.0 USD Million. Read More

What is the valuation range for the Severe condition segment in 2024?

The valuation range for the Severe condition segment in 2024 was between 615.69 and 950.0 USD Million. Read More

Which therapeutic area segment is projected to grow the most by 2035?

The Gastroenterology therapeutic area segment is projected to grow the most, with a valuation range of 800.0 to 1300.0 USD Million in 2024. Read More

What was the valuation for Mucosal Protective Agents in 2024?

The valuation for Mucosal Protective Agents in 2024 was between 352.29 and 737.92 USD Million. Read More

GERD and NERD Treatment Market

Q: Which key players are leading the GERD and NERD Treatment Market?

Key players leading the GERD and NERD Treatment Market include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Roche, Takeda, and Sanofi. Read More

ID: MRFR/Pharma/4106-CR

90 Pages

Vikita Thakur

Last Updated: March 27, 2026

Americas Gerd and Nerd Treatment Market Research Report Information, By Drug Class (Antacids (Acid Neutralizers), Proton Pump Inhibitors, H2 Receptor Blocker), Dosage Form (Solid And Liquid), End User (Hospitals and Clinics, Research Centers, And Others) -Forecast Till 2035

GERD and NERD Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.76%

2024 Market Size$ 2,052.29 Million

2025 Market Size$ 2,173.49 Million

2035 Market Size$ 3,437.92 Million

Key Players

AstraZeneca

Boehringer Ingelheim

GlaxoSmithKline

Johnson & Johnson

Novartis

Pfizer

Trends

Personalized Medicine
Minimally Invasive Procedures
Telemedicine Integration

Opportunities

Aging Population
Market Growth Projections
Increased Awareness and Diagnosis

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Million)
  1. 4.1.1 Proton Pump Inhibitors
  2. 4.1.2 H2 Receptor Antagonists
  3. 4.1.3 Antacids
  4. 4.1.4 Prokinetics
  5. 4.1.5 Mucosal Protective Agents
2. 4.2 Healthcare, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Intravenous
  3. 4.2.3 Topical
  4. 4.2.4 Rectal
3. 4.3 Healthcare, BY Patient Demographics (USD Million)
  1. 4.3.1 Adults
  2. 4.3.2 Pediatric
  3. 4.3.3 Geriatric
  4. 4.3.4 Pregnant Women
4. 4.4 Healthcare, BY Severity of Condition (USD Million)
  1. 4.4.1 Mild
  2. 4.4.2 Moderate
  3. 4.4.3 Severe
  4. 4.4.4 Chronic
5. 4.5 Healthcare, BY Therapeutic Area (USD Million)
  1. 4.5.1 Gastroenterology
  2. 4.5.2 Primary Care
  3. 4.5.3 Pediatrics
  4. 4.5.4 Obstetrics
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AstraZeneca (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Takeda (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
6. 6.6 US MARKET ANALYSIS BY SEVERITY OF CONDITION
7. 6.7 US MARKET ANALYSIS BY THERAPEUTIC AREA
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
11. 6.11 CANADA MARKET ANALYSIS BY SEVERITY OF CONDITION
12. 6.12 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
16. 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
17. 6.17 GERMANY MARKET ANALYSIS BY SEVERITY OF CONDITION
18. 6.18 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
20. 6.20 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
21. 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
22. 6.22 UK MARKET ANALYSIS BY SEVERITY OF CONDITION
23. 6.23 UK MARKET ANALYSIS BY THERAPEUTIC AREA
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
26. 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
27. 6.27 FRANCE MARKET ANALYSIS BY SEVERITY OF CONDITION
28. 6.28 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
31. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
32. 6.32 RUSSIA MARKET ANALYSIS BY SEVERITY OF CONDITION
33. 6.33 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
35. 6.35 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
36. 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
37. 6.37 ITALY MARKET ANALYSIS BY SEVERITY OF CONDITION
38. 6.38 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
41. 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
42. 6.42 SPAIN MARKET ANALYSIS BY SEVERITY OF CONDITION
43. 6.43 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY SEVERITY OF CONDITION
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
52. 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
53. 6.53 CHINA MARKET ANALYSIS BY SEVERITY OF CONDITION
54. 6.54 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
56. 6.56 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
57. 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
58. 6.58 INDIA MARKET ANALYSIS BY SEVERITY OF CONDITION
59. 6.59 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
62. 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
63. 6.63 JAPAN MARKET ANALYSIS BY SEVERITY OF CONDITION
64. 6.64 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY SEVERITY OF CONDITION
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
73. 6.73 MALAYSIA MARKET ANALYSIS BY SEVERITY OF CONDITION
74. 6.74 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
77. 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
78. 6.78 THAILAND MARKET ANALYSIS BY SEVERITY OF CONDITION
79. 6.79 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
82. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
83. 6.83 INDONESIA MARKET ANALYSIS BY SEVERITY OF CONDITION
84. 6.84 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
88. 6.88 REST OF APAC MARKET ANALYSIS BY SEVERITY OF CONDITION
89. 6.89 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
93. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
94. 6.94 BRAZIL MARKET ANALYSIS BY SEVERITY OF CONDITION
95. 6.95 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
98. 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
99. 6.99 MEXICO MARKET ANALYSIS BY SEVERITY OF CONDITION
100. 6.100 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
104. 6.104 ARGENTINA MARKET ANALYSIS BY SEVERITY OF CONDITION
105. 6.105 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SEVERITY OF CONDITION
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SEVERITY OF CONDITION
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SEVERITY OF CONDITION
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
125. 6.125 REST OF MEA MARKET ANALYSIS BY SEVERITY OF CONDITION
126. 6.126 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY SEVERITY OF CONDITION, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY SEVERITY OF CONDITION, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.2.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.2.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.3.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.3.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.4.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.4.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.5.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.5.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.6.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.6.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.7.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.7.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.8.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.8.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.9.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.9.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.10.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.10.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.11.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.11.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.12.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.12.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.13.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.13.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.14.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.14.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.15.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.15.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.16.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.16.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.17.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.17.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.18.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.18.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.19.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.19.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.20.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.20.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.21.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.21.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.22.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.22.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.23.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.23.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.24.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.24.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.25.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.25.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.26.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.26.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.27.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.27.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.28.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.28.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.29.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.29.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
  4. 7.30.4 BY SEVERITY OF CONDITION, 2025-2035 (USD Million)
  5. 7.30.5 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

GERD and NERD Treatment Market Segmentation

GERD and NERD Treatment Market By Treatment Type (USD Million, 2025-2035)

Proton Pump Inhibitors
H2 Receptor Antagonists
Antacids
Prokinetics
Mucosal Protective Agents

GERD and NERD Treatment Market By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Topical
Rectal

GERD and NERD Treatment Market By Patient Demographics (USD Million, 2025-2035)

Adults
Pediatric
Geriatric
Pregnant Women

GERD and NERD Treatment Market By Severity of Condition (USD Million, 2025-2035)

Mild
Moderate
Severe
Chronic

GERD and NERD Treatment Market By Therapeutic Area (USD Million, 2025-2035)

Gastroenterology
Primary Care
Pediatrics
Obstetrics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”